219 related articles for article (PubMed ID: 35482713)
1. Effects of ferric citrate and intravenous iron sucrose on markers of mineral, bone, and iron homeostasis in a rat model of CKD-MBD.
Biruete A; Metzger CE; Chen NX; Swallow EA; Vrabec C; Clinkenbeard EL; Stacy AJ; Srinivasan S; O'Neill K; Avin KG; Allen MR; Moe SM
Nephrol Dial Transplant; 2022 Sep; 37(10):1857-1867. PubMed ID: 35482713
[TBL] [Abstract][Full Text] [Related]
2. Effect of Advanced Glycation End-Products (AGE) Lowering Drug ALT-711 on Biochemical, Vascular, and Bone Parameters in a Rat Model of CKD-MBD.
Chen NX; Srinivasan S; O'Neill K; Nickolas TL; Wallace JM; Allen MR; Metzger CE; Creecy A; Avin KG; Moe SM
J Bone Miner Res; 2020 Mar; 35(3):608-617. PubMed ID: 31743501
[TBL] [Abstract][Full Text] [Related]
3. Effects of unfractionated heparin on renal osteodystrophy and vascular calcification in chronic kidney disease rats.
Meng Y; Zhang H; Li Y; Li Q; Zuo L
Bone; 2014 Jan; 58():168-76. PubMed ID: 24145307
[TBL] [Abstract][Full Text] [Related]
4. Phosphate binders for preventing and treating chronic kidney disease-mineral and bone disorder (CKD-MBD).
Ruospo M; Palmer SC; Natale P; Craig JC; Vecchio M; Elder GJ; Strippoli GF
Cochrane Database Syst Rev; 2018 Aug; 8(8):CD006023. PubMed ID: 30132304
[TBL] [Abstract][Full Text] [Related]
5. Segregating the effects of ferric citrate-mediated iron utilization and FGF23 in a mouse model of CKD.
Liesen MP; Noonan ML; Ni P; Agoro R; Hum JM; Clinkenbeard EL; Damrath JG; Wallace JM; Swallow EA; Allen MR; White KE
Physiol Rep; 2022 Jun; 10(11):e15307. PubMed ID: 35656701
[TBL] [Abstract][Full Text] [Related]
6. Effect of ferric citrate hydrate on fibroblast growth factor 23 and platelets in non-dialysis-dependent chronic kidney disease and non-chronic kidney disease patients with iron deficiency anemia.
Ito K; Akizawa T; Arita K; Mitobe Y; Komatsu N
Clin Exp Nephrol; 2024 Jul; 28(7):636-646. PubMed ID: 38402503
[TBL] [Abstract][Full Text] [Related]
7. Oral Versus Intravenous Iron Supplementation for the Treatment of Iron Deficiency Anemia in Patients on Maintenance Hemodialysis-Effect on Fibroblast Growth Factor-23 Metabolism.
Fukao W; Hasuike Y; Yamakawa T; Toyoda K; Aichi M; Masachika S; Kantou M; Takahishi SI; Iwasaki T; Yahiro M; Nanami M; Nagasawa Y; Kuragano T; Nakanishi T
J Ren Nutr; 2018 Jul; 28(4):270-277. PubMed ID: 29703633
[TBL] [Abstract][Full Text] [Related]
8. Ferric citrate reduces fibroblast growth factor 23 levels and improves renal and cardiac function in a mouse model of chronic kidney disease.
Francis C; Courbon G; Gerber C; Neuburg S; Wang X; Dussold C; Capella M; Qi L; Isakova T; Mehta R; Martin A; Wolf M; David V
Kidney Int; 2019 Dec; 96(6):1346-1358. PubMed ID: 31668632
[TBL] [Abstract][Full Text] [Related]
9. FGF23 neutralization improves chronic kidney disease-associated hyperparathyroidism yet increases mortality.
Shalhoub V; Shatzen EM; Ward SC; Davis J; Stevens J; Bi V; Renshaw L; Hawkins N; Wang W; Chen C; Tsai MM; Cattley RC; Wronski TJ; Xia X; Li X; Henley C; Eschenberg M; Richards WG
J Clin Invest; 2012 Jul; 122(7):2543-53. PubMed ID: 22728934
[TBL] [Abstract][Full Text] [Related]
10. Kidney Disease Progression Does Not Decrease Intestinal Phosphorus Absorption in a Rat Model of Chronic Kidney Disease-Mineral Bone Disorder.
Vorland CJ; Biruete A; Lachcik PJ; Srinivasan S; Chen NX; Moe SM; Hill Gallant KM
J Bone Miner Res; 2020 Feb; 35(2):333-342. PubMed ID: 31618470
[TBL] [Abstract][Full Text] [Related]
11. A review of ferric citrate clinical studies, and the rationale and design of the Ferric Citrate and Chronic Kidney Disease in Children (FIT4KiD) trial.
Hanudel MR; Laster ML; Portale AA; Dokras A; Quigley RP; Guzman GAL; Zaritsky JJ; Hayde NA; Kaskel FJ; Mitsnefes MM; Ramirez JA; Imani PD; Srivaths PR; Kogon AJ; Denburg MR; Blydt-Hansen TD; Reyes LZ; Greenbaum LA; Weidemann DK; Warady BA; Elashoff DA; Mendley SR; Isakova T; Salusky IB
Pediatr Nephrol; 2022 Nov; 37(11):2547-2557. PubMed ID: 35237863
[TBL] [Abstract][Full Text] [Related]
12. Effect of ferric citrate hydrate on FGF23 and PTH levels in patients with non-dialysis-dependent chronic kidney disease with normophosphatemia and iron deficiency.
Iguchi A; Yamamoto S; Yamazaki M; Tasaki K; Suzuki Y; Kazama JJ; Narita I
Clin Exp Nephrol; 2018 Aug; 22(4):789-796. PubMed ID: 29181658
[TBL] [Abstract][Full Text] [Related]
13. Effect of a Ferric Citrate Formulation, a Phosphate Binder, on Oxidative Stress in Chronic Kidney Diseases-Mineral and Bone Disorder Patients Receiving Hemodialysis: A Pilot Study.
Tanaka M; Miyamura S; Imafuku T; Tominaga Y; Maeda H; Anraku M; Yamasaki K; Kadowaki D; Ishima Y; Watanabe H; Okuda T; Itoh K; Matsushita K; Fukagawa M; Otagiri M; Maruyama T
Biol Pharm Bull; 2016; 39(6):1000-6. PubMed ID: 27251502
[TBL] [Abstract][Full Text] [Related]
14. Non-Additive Effects of Combined NOX1/4 Inhibition and Calcimimetic Treatment on a Rat Model of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD).
Damrath JG; Chen NX; Metzger CE; Srinivasan S; O'Neill K; Biruete A; Avin KG; Wallace JM; Allen MR; Moe SM
JBMR Plus; 2022 Mar; 6(3):e10600. PubMed ID: 35309859
[TBL] [Abstract][Full Text] [Related]
15. Effect of Ferric Citrate versus Ferrous Sulfate on Iron and Phosphate Parameters in Patients with Iron Deficiency and CKD: A Randomized Trial.
Womack R; Berru F; Panwar B; Gutiérrez OM
Clin J Am Soc Nephrol; 2020 Sep; 15(9):1251-1258. PubMed ID: 32694162
[TBL] [Abstract][Full Text] [Related]
16. The pathophysiology of early-stage chronic kidney disease-mineral bone disorder (CKD-MBD) and response to phosphate binders in the rat.
Moe SM; Radcliffe JS; White KE; Gattone VH; Seifert MF; Chen X; Aldridge B; Chen NX
J Bone Miner Res; 2011 Nov; 26(11):2672-81. PubMed ID: 21826734
[TBL] [Abstract][Full Text] [Related]
17. The relationship between urinary kidney injury molecule-1 and blood bone metabolism markers in patients with chronic kidney disease
.
Yin C; Cheng C; Wang J; Zhang L; Purrunsing Y; Yang G; Zeng M; Huang H; Ren W; Ye Y; Ma H; Xing C; Wang N
Clin Nephrol; 2020 Feb; 93(2):65-76. PubMed ID: 31793871
[TBL] [Abstract][Full Text] [Related]
18. Anemia and fibroblast growth factor 23 elevation in chronic kidney disease: homeostatic interactions and emerging therapeutics.
Agoro R; White KE
Curr Opin Nephrol Hypertens; 2022 Jul; 31(4):320-325. PubMed ID: 35703246
[TBL] [Abstract][Full Text] [Related]
19. Effect of ferric citrate on serum phosphate and fibroblast growth factor 23 among patients with nondialysis-dependent chronic kidney disease: path analyses.
Block GA; Pergola PE; Fishbane S; Martins JG; LeWinter RD; Uhlig K; Neylan JF; Chertow GM
Nephrol Dial Transplant; 2019 Jul; 34(7):1115-1124. PubMed ID: 30380116
[TBL] [Abstract][Full Text] [Related]
20. Parathyroid suppression therapy normalizes chronic kidney disease-induced elevations in cortical bone vascular perfusion: a pilot study.
Aref MW; Swallow EA; Metzger CE; Chen N; Moe SM; Allen MR
Osteoporos Int; 2019 Aug; 30(8):1693-1698. PubMed ID: 31069439
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
